In a report released yesterday, Michael Yee from Jefferies maintained a Buy rating on Fate Therapeutics (FATE), with a price target of $145.00.
The post Jefferies Maintains Their Buy Rating on Fate Therapeutics (FATE) appeared first on Smarter Analyst.
In a report released yesterday, Michael Yee ...

https://www.smarteranalyst.com/new-blurbs/jefferies-maintains-their-buy-rating-on-fate-therapeutics-fate/

#SmarterAnalyst